Six patients with AIDS and AIDS related complex (ARC) who developed neuromuscular symptoms associated with vesicular changes in muscle fibres are reported. Two patients in the advanced stages of AIDS, who did not receive zidovudine, developed proximal limb weakness and wasting: both had a necrotising myopathy with an unusual segmental vesicular change of myofibres. There were numerous vesicles 0-1 to 2 tm in diameter produced by dilatations of the sarcoplasmic reticulum in fibres depleted of myofibrils. Four patients developed a myopathy while receiving zidovudine for AIDS. One of these had an inflammatory myopathy which showed the development of vesicular change due to enlargement and electron lucency of mitochondria. The three other patients with ARC developed muscle pains or weakness and elevated serum CK while on zidovudine. These patients also showed vesicular changes due to enlargement and electron lucency of mitochondria associated with disruption of sarcomeres and the presence of cytoplasmic bodies. The muscular symptoms resolved when zidovudine was stopped and repeat biopsy in one case revealed no abnormalities.
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Central and peripheral nervous system complications are features of the acquired immune deficiency syndrome (AIDS).'2 Disorders of voluntary muscle have also been described. Among these, inflammatory myopathy,3 4 inflammatory myopathy with giant cells,5 necrotising myopathy with minimal inflammatory infiltrate,6 7 myopathy with rod bodies,89 and type 2 fibre atrophy'01' have been recorded. Recently we described two AIDS patients who had myopathy characterised by vesicular changes by light microscopy-a rather unique myopathic reaction which occurred in the absence of zidovudine treatment. '2 In this study we present the ultrastructural findings of these two patients and four other AIDS patients who also developed vesicular changes in skeletal muscle while receiving zidovudine.
Materials and methods
Skeletal muscle for study from the right biceps brachii and quadriceps femoris was derived by local incision within 30 minutes after the death of patients 1 and 2 (see below). Permission for a general necropsy was refused in both. Muscle specimens were processed for paraffin embedded blocks, and formalin fixed frozen sections for ORO and PAS stains. Fibre typing was performed on paraffin sections using a monoclonal antibody to fast myosin (ICN products). The paraffin-embedded blocks were stained with haematoxylineosin, picro-mallory, Fite-Faraco, Methanamine silver, Giemsa, Gram, and Ziehl-Neelsen stains.
For electron microscopy the samples were fixed in 2 5% gluteraldehyde in phosphate buffer (pH 7A4) for Electron Microscopy Ultrastructure of the first biopsy showed a patchy loss of myofibrils with irregularities of Z and I bands. Several cytoplasmic bodies were identified adjacent to aggregates of swollen mitochondria. The muscle nuclei, sarcolemma, and sarcoplasmic reticulum were normal. Virus particles were not found. The second biopsy showed in several fibres the accumulation of abnormal enlarged (5-7 jm) mitochondria which possessed numerous cristae which on occasions were concentrically arranged. In addition myofibrillary disorganisation and increase in the number of lipid globules were also seen in such fibres. Many mitochondria of near normal size had distorted cristae, vesicles and electron dense deposits in their inner chamber (fig 4) . Other myofibres showed minicores, cytoplasmic bodies, and excess lipid globules. The sarcoplasmic reticulum was normal. The third biopsy showed similar mitochondrial abnormalities associated with myofibrillary disorganisation, cytoplasmic bodies, and Z band streaming. myopathic effect by disturbing mitochondrial structure and function. The abnormalities of mitochondria structure described here are similar to those recorded in the drug induced myopathies, namely chloroquine and emetine, where there is derangement of cristae and eventual mitochondrial disruption as we have found.6 17 Our studies confirm previous reports of a necrotising non-inflammatory myopathy associated with zidovudine treatment. 8 9However, we believe vesicular change due to dilatations of the SR described above, is a distinct entity unrelated to zidovudine. In the presence of zidovudine, vesicular change in muscle fibres is due to vacuolation of mitochondria unrelated to the SR. Vacuolation of muscle has been described in AIDS in the presence and absence of zidovudine treatment. In the report by Stern et al 1987 the vacuolation measured 10-50 gm, and was centrally located within the myofibre.4 The vesicular changes as described by us were not found. Mitochondrial ultrastructural abnormalities were not reported in a patient who received zidovudine and developed vacuolation of muscle described by Gorard et al 1988 . '9 Vacuolation of voluntary muscle is recognised in the so called vacuolar myopathies and includes periodic paralyses, inclusion body myositis, lipid storage myopathies, glycogenoses, and the oculopharyngeal myopathies. 20 The diagnoses were excluded clinically and pathologically. The vacuoles in these conditions measure 10-50 um in diameter unlike the 0-1-2 um vesicles found in our cases.
In conclusion, we have described two distinct myopathological entities in AIDS. The first disorder occurs in the absence of zidovudine treatment, and is characterised by vesicular change by light microscopy due ultrastructurally to dilations of the sarcoplasmic reticulum and probably represents a unique cytopathic effect analogous to the "foamy degeneration" associated with other retroviruses.2'22 The second entity occurs in the presence of zidovudine treatment and is also characterised by vesicular change by light microscopy but this change is due to enlargement and electron lucency of mitochondria which also show abnormal cristae. Zidovudine is a nucleoside analogue which inhibits the in vitro replication of human immunodeficiency virus and reduces the intracellular pool of pyrimidines23 which suggests that it may interfere with the homeostasis of mitochondrial DNA in muscle.
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